Document Detail

Trial watch: Chemotherapy with immunogenic cell death inducers.
MedLine Citation:
PMID:  22720239     Owner:  NLM     Status:  Publisher    
The long-established notion that apoptosis would be immunologically silent, and hence it would go unnoticed by the immune system, if not tolerogenic, and hence it would actively suppress immune responses, has recently been revisited. In some instances, indeed, cancer cells undergo apoptosis while emitting a spatiotemporally-defined combination of signals that renders them capable of eliciting a long-term protective antitumor immune response. Importantly, only a few anticancer agents can stimulate such an immunogenic cell death. These include cyclophosphamide, doxorubicin and oxaliplatin, which are currently approved by FDA for the treatment of multiple hematologic and solid malignancies, as well as mitoxantrone, which is being used in cancer therapy and against multiple sclerosis. In this Trial Watch, we will review and discuss the progress of recent (initiated after January 2008) clinical trials evaluating the off-label use of cyclophosphamide, doxorubicin, oxaliplatin and mitoxantrone.
Erika Vacchelli; Lorenzo Galluzzi; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Guido Kroemer
Related Documents :
22706169 - Opposed arsenite-mediated regulation of p53-survivin is involved in neoplastic transfor...
22697169 - Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity.
22847239 - Adaptive immunity in obesity and insulin resistance.
22363399 - Palmitate promotes the paracrine effects of macrophages on vascular smooth muscle cells...
8485449 - Cytokines in neuronal cell types.
22720239 - Trial watch: chemotherapy with immunogenic cell death inducers.
21986309 - An in vitro reconstitution system to address the mechanism of the vascular expression o...
8425209 - Effect of lentinan on macrophage cytotoxicity against metastatic tumor cells.
15662369 - Host persistence: exploitation of anti-inflammatory pathways by toxoplasma gondii.
Publication Detail:
Journal Detail:
Title:  Oncoimmunology     Volume:  1     ISSN:  2162-402X     ISO Abbreviation:  Oncoimmunology     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-6-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101570526     Medline TA:  Oncoimmunology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  179-188     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A systematic analysis of experimental immunotherapies on tumors differing in size and duration of gr...
Next Document:  The role of innate immune signals in antitumor immunity.